Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M. Furaha Kariburyo, MPH Value in Health Regional Issues Volume 7, Pages 42-48 (September 2015) DOI: 10.1016/j.vhri.2015.08.004 Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 1 Patient selection criteria. HCV, hepatitis C virus; Peg-IFN-α, pegylated interferon-alpha. Value in Health Regional Issues 2015 7, 42-48DOI: (10.1016/j.vhri.2015.08.004) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions